Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAG200 in Knee Osteoarthritis (nexcell-OAK)
NCT07106229Phase 3Not yet recruiting
- Sponsor
- Magellan Stem Cells
- Start
- Nov 2025
- Primary completion
- Feb 2028
- Modality
- Mesenchymal Stem Cells
01
Overview
A Phase 3 trial of MAG200 in osteoarthritis (OA), sponsored by Magellan Stem Cells. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
MAG200
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT07106229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07106229.